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Abstract
Bachmann-Bupp syndrome (BABS) is a rare syndrome caused by gain-of-function
variants in the C-terminus of ornithine decarboxylase (ODC coded by the ODC1
gene). BABS is characterized by developmental delay, macrocephaly, macrosomia,
and an unusual pattern of non-congenital alopecia. Recent diagnosis of four more
BABS patients provides further characterization of the phenotype of this syndrome
including late-onset seizures in the oldest reported patient at 23 years of age, rep-
resenting the first report for this phenotype in BABS. Neuroimaging abnormalities
continue to be an inconsistent feature of the syndrome. This may be related to the
yet unknown impact of ODC/polyamine dysregulation on the developing brain in this
syndrome. Variants continue to cluster, providing support to a universal biochemical
mechanism related to elevated ODC protein, enzyme activity, and abnormalities in
polyamine levels. Recommendations for medical management can now be suggested
as well as the potential for targeted molecular or metabolic testing when encounter-
ing this unique phenotype. The natural history of this syndrome will evolve with dif-
luoromethylornithine (DFMO) therapy and raise new questions for further study and
understanding.
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1 | INTRODUCTION
Ornithine decarboxylase 1 (ODC1) is a key gene coding for an enzyme
(ODC) in the polyamine (PA) pathway, a metabolic system important
for embryogenesis, organogenesis, and neoplastic cell growth (Casero
Jr. & Marton, 2007; Gerner & Meyskens Jr., 2004; Pegg, 2016; Pegg &
McCann, 1982; Wallace et al., 2003). A recently established OMIM
entry (#619075) called Bachmann-Bupp Syndrome (BABS) is caused
by gain-of-function variants in the C-terminus of ODC and is charac-
terized by alopecia, developmental delay, macrosomia, macrocephaly,
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and some dysmorphic features (Bupp et al., 2018; Rodan et al., 2018).
Laboratory analysis of patient samples demonstrated elevated ODC
protein, ODC enzymatic activity levels, and abnormal PA levels
(i.e., increase in putrescine) in affected patients. Treatment of patient-
derived primary dermal fibroblasts with ODC inhibitor eflornithine
(aka difluoromethylornithine; DFMO) showed normalization of these
levels (Schultz et al., 2019). This suggested the potential for treatment
as DFMO has previously been shown to be tolerated in the treatment
of African sleeping sickness (trypanosomiasis) (Alirol et al., 2013;
Priotto et al., 2009) and pediatric neuroblastoma (Lewis et al., 2020;
Saulnier Sholler et al., 2015). In addition, a previously developed trans-
genic mouse model showed alopecia with resolution after treatment
with DFMO (Megosh et al., 1995; Soler et al., 1996). Adding genotype
and phenotype information from four additional patients to the five
individuals already reported helps further characterize this syndrome
and its natural history, which is of particular importance in lieu of the
potential for treatment early in the disease course.
2 | CASE PRESENTATIONS
2.1 | Patient 6
This patient is a 9-year-old Caucasian boy at the time of reporting and
was born at 39 weeks gestation after an uncomplicated pregnancy. At
birth, he measured at the 87th percentile (52 cm) for height, 36th per-
centile (3170 g) for weight, and greater than 36th percentile (34 cm)
for head circumference based on World Health Organization (WHO)
0–2 years standard growth curves. Examination at age 9 identified
height at the 42nd percentile (134 cm), weight in the 23rd percentile
(26,400 g), and head circumference at the 90th percentile (54.4 cm)
based on CDC 2–18 years standard growth curves. He walked
independently at 25 months, spoke his first words at 3 years, and
was toilet trained at 9 years. At 4.5 years, he could speak in 3–
4-word sentences, exhibiting limited verbal capacity. He is
reported to have an intellectual disability with an IQ of 55 and
behavioral concerns that include stubbornness, although he has
good social skills. Brain MRI identified hypoplastic chiasma, tractus
opticus, and a small pituitary gland. Past medical history also
includes hypotonia, ataxia, significant constipation, keratosis pilaris
on the upper and lower limbs and cheeks, significantly reduced
sweating, and reduced sensitivity to pain. Dysmorphic facial fea-
tures include sparse eyebrows and eyelashes, sparse scalp hair
only in early childhood with current scalp hair being shaggy and
dry, broad forehead, elongated face, low anterior hairline,
infraorbital fold, hypertelorism, narrow bridge of nose, thick and
anteverted nasal alae, low insertion of the columella, deep and
short philtrum, everted lower and tented upper lip vermillion,
prominent maxillary central secondary incisor teeth and diastema
of the upper and lower central incisors, prominent and pointed
chin, and large earlobes (Figure 1). Other distinctive physical char-
acteristics are hypertrichosis on the back, pectus carinatum supe-
rior with excavatum inferior, winged scapulae, bilateral cubitus
valgus, long fingers and broad terminal phalanges, and bilateral
genu varum.
He has a history of a previous nondiagnostic chromosomal micro-
array. He was identified to have a de novo heterozygous variant in
the ODC1 gene, c.1242-2A>G, (IVS11-2A>G) that is predicted to
F IGURE 1 Representative clinical phenotypes from cases 6 to 8. The first three panels show the physical facial phenotypes of the patient
presented in Case 6 at ages 1, 4, and 9 years. The fourth panels demonstrate the hair loss seen from birth (top panel) to age 1 month (bottom
panel) for the patient presented in Case 7, as well as the physical facial phenotype of the same patient in the fifth panels. The last panels show
the physical facial phenotypes as well as hair loss of the patient presented in Case 8 at age 23 years
2 VANSICKLE ET AL.
destroy a canonical splice acceptor site in intron 11. This variant is not
observed in large population cohorts (Lek et al., 2016; 1000 Genomes
Consortium, 2015; Exome Variant Server).
2.2 | Patient 7
This patient is a 6-year-old Caucasian boy at the time of reporting and
was born after a pregnancy complicated by polyhydramnios. He was
born at 38 weeks with APGAR scores of 3 and 7. At age 5, his height
was in the 29th percentile, weight at the 11th percentile, and head
circumference at the 42nd percentile. He spoke his first words at
4.5 years, was not walking yet at examination, with a degree of intel-
lectual disability. Brain MRI at age 2 identified non-specific T2 hyper-
intensities, but was otherwise unremarkable. Small atrial
communication was identified on echocardiogram at age 4. Past medi-
cal history also includes hypotonia, left gaze prominence, nutrition
drink and protein shake supplementation due to poor feeding and fail-
ure to thrive, constipation, gastroesophageal reflux, ventricular septal
defect that spontaneously closed, and syringohydromyelia that
resolved by age 3. Hair at birth was notable for band of alopecia
between sparse hair on calvaria and neck which fell out within the
first month of life (Figure 1). Sparse hair is now present throughout
the scalp with very little eyebrow hair and eyelashes. He has a history
of recurrent follicular cysts on the head, ears, and axilla, some of
which have required surgical drainage. Dysmorphic features include a
long face, broad forehead, sagittal craniosynostosis, cryptorchidism,
and choanal atresia.
Prior whole-exome sequencing (WES) was non-diagnostic.
Whole-genome sequencing (WGS) through the Undiagnosed Diseases
Network demonstrated a de novo heterozygous variant in the ODC1
gene, c.1313_1316delCTGT (p.438Rfs*9), which causes a disruption
in this reading frame, leading to the entire DNA sequence following
the mutation to be read incorrectly. This variant is absent in large pop-
ulation cohorts (Broad gnomAD database).
2.3 | Patient 8
This patient is a 23-year-old Caucasian male at the time of reporting
and was born after a pregnancy complicated by cephalopelvic dispro-
portion. He was born at 40 weeks with APGAR scores of 8 and 9. At
birth, he was reported to be in the 99th percentile (55 cm) for height
and 95th percentile (4218 g) for weight based on WHO 0–2 years
standard growth curves. He was noted to be macrocephalic (>99.9%
WHO) at birth (40 cm), which has been a consistent finding on his
physical exam since. He is reported to have lack of motor coordina-
tion, independent walking at 4 years old, as well as oro-motor
dyspraxia and speaking his first words at age 6. He is reported to have
moderate intellectual disability, being unable to engage in linear con-
versation. At age 19, he had a psychological evaluation that diagnosed
him with anxiety, disruptive behavior, mild aggression, poor social and
coping skills, difficulties in academic performance, and self-injurious
behaviors. A series of brain MRIs have consistently identified non-
specific white matter signal changes as well as parenchymal and hip-
pocampal volume loss advanced for age. This patient was diagnosed
with absent seizures at age 14 years. At that time, he was placed on
sodium valproate and remained seizure free for 2 years, but the treat-
ment led to fatty liver and hair loss. No controlling medication has
since been identified, with vagal nerve stimulator implanted at age
20, which exacerbated the seizures and recent ketogenic diet that
showed no improvement. He has multiple seizure types but atypical
absence, atonic, and generalized tonic–clonic are common. Most
recent EEG performed at age 23 identified severely abnormal EEG
with multiple short bursts of low voltage generalized spikes, abundant
multifocal spikes, and generalized background slowing. This patient's
history is significant for alopecia affecting the scalp, eyelashes, eye-
brows, and axillary and pubic hair with sparse arm and leg hair that
was initially reversible but has been stably at a loss in recent years.
Previous medical history includes hypotonia and skin findings includ-
ing a hemangioma, pigmented nevus, and multiple scattered hyper-
pigmented macules. Dysmorphic facial features noted include bilateral
epicanthal folds, high palate, slight facial asymmetry with drooping of
the left mouth corner, frontal bossing, dolichocephaly, and kyphosis
(Figure 1).
High hCG and low uE3 on prenatal triple screen caused the family
to pursue a prenatal karyotype, which was normal. At age 11, PTEN
testing was negative. At age 10, microarray identified a 12p13.32
duplication, which was later identified to also be present in his asymp-
tomatic father. This finding was replicated on microarray ordered at
age 19. Also, at age 19, he had normal very long chain and branched-
chain fatty acid analysis as well as normal free and total carnitine.
WES at age 20 identified a homoplasmicMT-ATP8 m.8553C>T variant
of uncertain significance, RTTN c.2738T>C paternal variant of uncer-
tain significance, RTTN c.5572C>G maternal variant of uncertain sig-
nificance, RTTN c.590G>A maternal variant of uncertain significance,
and heterozygous de novo variant in the ODC1 gene, c.1242-2A>G
(IVS11-2A>G). The ODC1 variant is predicted to destroy a canonical
splice acceptor site in intron 11. This variant is not observed in large
population cohorts (Lek et al., 2016; 1000 Genomes
Consortium, 2015; Exome Variant Server).
2.4 | Patient 9
This patient is a 1.5-year-old Caucasian female at the time of
reporting and was born at 41 weeks gestation after an uncomplicated
pregnancy with APGAR scores of 6, 6, and 6. At birth, she required
resuscitation with oxygen, bag-mask ventilation, and eventual CPAP.
She was admitted to the NICU for a possible perinatal infection. Her
birth weight was in the 87th percentile (3780 g) and head circumfer-
ence was greater than 99th percentile (38.5 cm) using WHO
0–2 years standard growth curves. Height measured on day 14 of life
was in the 99th percentile (54 cm) using WHO 0–2 years standard
growth curves. Examination at 10 months identified height in the
98th percentile (75.3 cm), weight in the 73rd percentile (9500 g), and
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head circumference greater than the 99th percentile (49 cm) using
WHO 0–2 years standard growth curves. She was noted to have axial
hypotonia which delayed her walking until 17 months. At the time of
reporting, she does not have any words. Brain MRI identified frontal
cortex decreased gyration, germinal cysts, and left porencephalic cyst,
and frontal and parietal white matter hyperintensity. Echocardiogram
identified mild pulmonary stenosis with mild insufficiency. Dysmor-
phic features include sparse hair and eyebrows that are improving
with time, hypertelorism, mild retrognathism, broad forehead, and
macrocephaly.
Prior genetic testing included a microarray, which identified
an 83 kb duplication of 18q21.32. Trio WES demonstrated a de
novo heterozygous variant in the ODC1 gene, c.1252C>T (p.
Gln418*), which causes premature termination of the protein. This
variant is not observed in large population cohorts (Broad
gnomAD database).
3 | RESULTS
Adding these new patients to those five individuals previously
reported (Bupp et al., 2018; Rodan et al., 2018), patients with BABS
now total 6 males and 3 females. All variants are de novo with no
patients having a second contributory genetic diagnosis. Previous
genetic testing is variable with most patients having nondiagnostic
chromosomal microarray. Metabolic testing was performed on some,
and 2 of 4 newly reported patients had previous WES that was non-
diagnostic with a diagnosis made for one patient on re-analysis after
initial description of this syndrome and the other by WGS. Poly-
hydramnios was seen in the majority of patients (four of seven) and
gestational age appears to be within normal limits. Head circumfer-
ence appears to be larger at birth, along with length but not typically
weight. The one patient without macrocephaly has sagittal craniosyn-
ostosis, which has not been surgically corrected. Postnatal complica-
tions are not consistent. Global developmental delay is uniform with
this syndrome, typically in the more severe range with associated
behavior concerns. The earliest walking was at 17 months but often
not until 3–4 years of age. Speech appears limited with first words at
2–3 years and some patients remain nonverbal. Muscular hypotonia is
also a common feature in all eight living individuals. Every patient had
a brain MRI performed at some time point, and neuroimaging abnor-
malities are common, but not with a particular pattern or recurrence
of findings.
Alopecia is a notable feature of this condition, particularly since
this is not present at birth, but often occurs shortly after birth with
hair loss in large sections. (Figure 1, Patient 7). Description of physical
features does not suggest a particular pattern of dysmorphism of all
recognizable facial features except for the broad forehead/
macrocephaly. Cryptorchidism is present in three of six males. Cardiac,
pulmonary, or hepatic involvement seems to be variably present. Con-
stipation, a common ailment and even more common in general with
patients with developmental delay, is present in three of seven
patients (Table 1).
Novel findings in these newly reported patients include the first
report of seizures, with onset at age 14 years. These seizures have
been resistant to treatment. This patient presented as Patient
8, 23 years old at reporting, is also the oldest patient now known to
have this syndrome. Genotype findings continue to show variants in
the C-terminus of the ODC protein. In the biochemical pathway,
destabilization of this region blocks protein degradation and leads to
ODC accumulation. This results in elevation in putrescine and acetyl-
putrescine, but not other PAs. Finally, we also observe the first recur-
rent variant for this syndrome (c.1242-2A>G; p.IVS11-2A>G) in
Patients 6 and 7 (Figure 2).
4 | DISCUSSION
The additional patients described here along with the oldest reported
patient, allow for a broader description of the spectrum of this disor-
der and expansion of the history. Common findings include develop-
mental delay, hypotonia, and varying degrees of alopecia, typically
soon after birth. All patients underwent brain imaging with the larger
head size and developmental delay being the indication. The findings
on imaging however appear to be inconsistent. Brain development is a
complex process, and the ubiquitous functionality of the PA pathway
lends itself as a potential target for downstream abnormality. Further
understanding of the mechanism for brain anomalies in this syndrome
is necessary, particularly considering that it could potentially impact
treatment. Patient 8 is notable for developing epilepsy, but the later
onset could mean that the younger patients are at risk for future
development of seizures. Anti-epileptic and Vagus Nerve Stimulation
(VNS) treatment has had a limited impact with the seizures being
resistant to ketogenic diet. The initiation of this diet is challenging at
best and the variable PA content of various foods may present a
unique conundrum for clinicians in the future (Muñoz-Esparza
et al., 2019). It remains unclear whether therapies that are directed at
PA levels have a role to play in controlling seizures.
Macrocephaly continues to be a consistent finding in most cases;
however, macrosomia now does not. At this time, it would be a rea-
sonable to consider macrocephaly to be a key feature of the syn-
drome while viewing macrosomia with less certainty. Further
correlation of birth growth parameters and serial monitoring of height,
weight, and head circumference may inform this over time. The find-
ing of craniosynostosis in one patient without macrocephaly does
explain lack of macrocephaly, although craniosynostosis has not been
seen in other patients. The role of PAs in growth may relate to patient
size at birth and throughout life, potentially impacted as well by devel-
opmental delay and the impact of that on feeding and nutrition.
All diagnoses to date have been made using broad sequencing,
such as WES or WGS. The potential for this syndrome to be
suggested by metabolic testing is limited by the availability of PA-
specific testing assays. Global metabolomic testing could raise the
possibility of this diagnosis. As both molecular and metabolomic test-
ing capabilities expand in scope and access, as well as costs for both
potentially decrease, more individuals of BABS may be identified. The
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natural history of rapid hair loss shortly after birth appears to be
unique to this syndrome and could be a reason for consideration of
targeted ODC1 gene analysis when observed in any patient with
developmental delay.
Recommendations for screening and management for BABS can
start to be formulated. Much of this is more generalizable to other
neurodevelopmental disorders, such as the risk of vision and hearing
concerns requiring screening or the potential for constipation possi-
bly related to the common finding of hypotonia. No consistent con-
cerns were noted on echocardiogram or abdominal imaging,
suggesting the need only for symptomatic management. Develop-
mental assessment and intervention, such as physical and speech
therapy are recommended; particularly as developmental milestones
vary in patients. Additional support may be required for more
severely affected patients. As more is known about treatment with
DFMO, the natural history of neurocognitive findings in this syn-
drome may change (Rajasekaran et al., 2021). Diagnoses like autism
spectrum disorder (ASD) and intellectual disability (ID) may become
more apparent as cognitive and behavioral development progresses
functionality to the level of being able to make that diagnosis with
more confidence.
5 | CONCLUSION
Four new patients of BABS further confirm the phenotypic descrip-
tion of a recognizable syndrome characterized by developmental
delay, macrocephaly, and rapid appearance of alopecia shortly after
birth. Causative variants cluster in the C-terminus of the ODC protein.
With further disease description and knowledge, more diagnoses may
be made early in disease course allowing potential intervention
with DFMO.
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